Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2012

View Archived Issues

CAP-7.1 evaluated in patients with solid tumors

Sarepta Therapeutics enters collaboration for DMD drug

miRNA-768-3p is downregulated in human GBM cells

Autophagy-related proteins correlate with acute myelogenous leukemia prognosis

Lilly Japan set to launch Zyprexa intramuscular injection

EMA accepts for review MAAs for vintafolide and etarfolatide

Novel IL-4/IL-13 binding proteins patented by Janssen Biotech and Molecular Partners

Unigene and Tarix enter licensing agreement for TXA-127

FDA clears Avaxia Biologics' IND for AVX-470

Amakem patents new ROCK-II inhibitors

ChemoCentryx begins phase I trial of CCX-872

Panacela Labs signs contract with Russian Ministry of Industry and Trade

Novel agents for the treatment of myocardial infarction disclosed by Grindeks

MMRF partners with the Department of Veterans Affairs

Gilead Sciences reports results from phase III sofosbuvir trial

Johns Hopkins researchers develop pan-malaria transmission-blocking vaccine

Phase III pimavanserin study meets primary endpoints

Japanese scientists present new humanized monoclonal antibodies

Ruga presents next-generation B-raf V600E inhibitors

Amgen synthesizes novel protein kinase inhibitors

Phase II study of ProHema for hematologic malignancies begins

U.K.'s NICE selects ThromboGenics' Jetrea for single technology appraisal

Trial of Bayer's investigational hemophilia treatment completes recruitment of first cohort

European Commission approves Viread for two new indications

Forest Laboratories submits NDA for cariprazine in two mental health disorders

Almirall reports novel PI3Kdelta inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...